At BeiGene, we are passionate about our people, science, and creating a lasting impact. These priorities are of utmost importance to our organization. We strive to build a global organization recognized for its impact in cancer research and drug development, talented people, and integrity.
Learn about ‘Our Story’
Our Founders
Our founders united to benefit patients with cancer – wherever they live – by building a unique operating model, founded on the belief that innovative, impactful and high-quality medicines can be made faster and more affordable around the world.
“We think differently. We strive for innovation and excellence to make what seemed impossible into reality.”
John V. Oyler
Co-Founder, Chairman and CEO
“At BeiGene, we are dedicated to developing best-in-class anti-cancer therapies for China and the world. It’s an important mission and one we are intent on accomplishing.”
Xiaodong Wang
Chairman of Scientific Advisory Board & Co-Founder
Global Reach
From our start in Beijing with a handful of scientists and developers, we now have a global team, a rich pipeline, strong partnerships, and commercial products. We have no borders.
As part of our clinical development program, we are enrolling patients in 45+ geographies to participate in over 140 clinical trials.
Today, we are more than 10,000 colleagues across five continents. We have built sustainable competitive advantages including predominantly fully integrated global clinical development, science-based commercial teams in China, the U.S., and Europe, a robust research pipeline, and state-of-the-art internal manufacturing capabilities.
Our Passion
At BeiGene, we are passionate about our people, science, and creating a lasting impact. These priorities are of utmost importance to our organization. We strive to build a global organization recognized for its impact in cancer research and drug development, talented people, and integrity.
Our Science
The future of cancer innovation is underway, and we are dedicated to leading the charge.
BeiGene Cancer Biology Platform
Our focus is on molecularly targeted and immuno-oncology cancer therapeutics, both as monotherapies and for use in combination treatments, to have a meaningful and lasting impact on cancer patients.
Our development strategy facilitates R&D and commercialization around the world, with an emphasis on:
Independent R&D of Innovative oncology therapies
Molecularly Targeted Agents
Immuno-Oncology Therapies
Combination
Strategic collaboration with Global Partners
Established collaborations help leverage our capabilities in China and expand our portfolio
Evolution of BeiGene
An unprecedented journey to serve patients
†For a full listing of collaborative partners, please refer to slide: BeiGene – Striving to be the Partner of Choice CLL=chronic lymphocytic leukemia, FDA=Food and Drug Administration, IPO=initial public offering, MCL=mantle cell lymphoma, NDA=New Drug Application, R/R cHL=relapsed/refractory classical Hodgkin’s lymphoma, SLL=small lymphocytic lymphoma, WM=Waldenström macroglobulinemia 1. BeiGene. https://www.beigene.com/partnering/partnering-with-beigene. Accessed 30Oct20. 2. Dealogic data. 3. BeiGene Press Release. 17Jun21. Available at: https://ir.beigene.com/news-events/press-releases/. Accessed 13Aug21. 4. BeiGene Press Release. 08Apr21. Available at: https://ir.beigene.com/news-events/press-releases/. Accessed 13Aug21 5. BeiGene Press Release. 05Aug21. Available at: https://ir.beigene.com/news-events/press-releases/. Accessed 13Aug21
Lasting Impact
Recognized for our cancer research and drug development, the quality of our work, and our integrity.
BeiGene Key Principles
Patient-motivated
We are driven, by altruism and unrelenting curiosity, to develop innovative medicines intended to be accessible to large and broad populations.
Innovation-Driven
We have a novel and global business model intended to effectively and efficiently translate groundbreaking science into medical innovation.
Quality-Focused
To build a company that will have a lasting impact, we are focused on doing everything to the highest standards of quality. There are no shortcuts to longevity.
beigenemedical.info
Our platform provides state-of-the-art content for healthcare professionals in the field of cancer treatment. The future of cancer innovation is underway, and we are dedicated to sharing the knowledge.